CSI Market
Sign In | Register

Insight Molecular Diagnostics Inc (IMDX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IMDX quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Insight Molecular Diagnostics Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-0.05
Depreciation & amortization2.19
Amortization of Other Assets0.01
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability20.55
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.04
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation2.22
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized-0.19
Debt Conversion Converted Instrument Amount-
Amortization Of Prepaid Maintenance-
Dividend Income Operating-
Amortization Of Right Of Use Assets And Liabilities-
Increase Decrease In Operating Lease Liability-0.29
Change In Fair Value Of Series Redeemable Convertible Preferred Stock Second Tranche Obligation-
Accrued Severance From Chronix Biomedical Acquisition-
Equity Compensation For Bonus Awards And Consulting Services0.16
Income taxes15.20
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.49
Increase (Decrease) in Accounts Payable and Accrued Liabilities2.65
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.23
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-22.18
Investing Activities
Capital Expenditures-3.19
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Security Deposit Received-
Security Deposit Payment-
Payments To Security Deposit And Other-
Payments For Equity Method Investment-
Acquisition Of Razor Genomics Asset Net Of Cash Acquired-
Payment For Cash Sold In Discontinued Operations-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-3.19
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock28.66
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.07
Other net-0.51
Proceeds From Issuance Of Common Shares And Warrants-
Proceeds From Sale Of Common Shares And Warrants-
Financing Costs To Issue Common Shares And Warrants-
Finance Lease Principal Payments-
Repayments Of Principal And Bank Fees From Refinancing Of Bank Loan-
Common Shares Received And Retired For Employee Taxes Paid-
Repayment Of Principal And Bank Fees From Refinancing Of Bank Loan-
Payment For Financing Costs For Atthemarket Sales-
Repayment Of Financing Lease Obligations-0.20
Proceeds From Sale Of Common Shares Under At The Market Transactions1.80
Payment Of Financing Costs For At The Market Sales-0.42
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities28.07
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-25.37
Total Cash Flow2.58
4 historic quarters locked

Sign in to unlock the full Insight Molecular Diagnostics Inc cash flow history.

Sign In Create Free Account

About Insight Molecular Diagnostics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001642380-26-000004

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License